Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 20

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 20
---
. Distributing vaccines, especially those requiring specific storage conditions or administration routes, can pose logistical challenges, particularly in resource-limited settings. The evolution of new virus variants may affect vaccine effectiveness, requiring ongoing monitoring and potential vaccine modifications.

| We may not be successful in establishing and                                                                                     
 maintaining development and commercialization collaborations, which could adversely affect our ability to develop certain of our 
 product candidates and our financial condition and operating results.                                                            |

A key part of our business plan is to establish and cultivate long-term relationships with strategic partners, including collaborations with global health organizations, like WHO and NIH, NGOs, and government health organizations. These partnerships can facilitate market access, drive adoption, and support public health initiatives. We must successfully contract with these and other third parties to develop and market our novel technology. We are evaluating additional potential partnerships and collaborative agreements as a way to further fund operations, but there is no assurance we will be able to secure partnerships or other arrangements and to negotiate commercially acceptable licensing or other agreements for the future exploitation of our novel technology, including the continued clinical development, manufacture or marketing of our novel technology. If we are unable to successfully contract for these services, or if arrangements for these services are terminated, we may have to delay our commercialization program for our novel technology, which will adversely affect our ability to generate operating revenues.

The success of our business operations is dependent on our ability to successfully develop our products and to complete clinical programs. We cannot assure you that we will successfully develop any products, or if we do, that they will be commercially successful.

Our ability to achieve and sustain operating profitability depends on our ability, directly or with strategic partners, to successfully commercialize our products in Europe, Asia and in the US. This will depend in large part on our ability to commence, execute and complete clinical programs and obtain regulatory approvals for our products.

Clinical trials are necessary before we can seek regulatory approval to sell our products. We cannot assure you that we will receive approval for our products in the United States or in other countries or, if approved, that we or a partner will achieve a significant level of sales, or that we develop any products. If we fail to partner, develop or commercialize our products, we may be forced to curtail or cease operations.

We are also in the pre-clinical stages of research and development with the vaccine and ARB new product candidates using nanoparticles-based technologies. These new indications and product candidates will require significant costs to advance through the development stages. Even if such product candidates are advanced through clinical